Close Menu

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Molecular Response today announced a joint research and development deal with Scripps Genomic Medicine targeting oncology and cardiovascular disease.

The deal calls for Molecular Response to fund up to two discovery programs in the two indications. In return, Scripps will grant the San Diego-based firm exclusive intellectual property rights.

Further financial and other terms of the agreement were not disclosed.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The New York Times looks at companies using genomic tools to try to quickly identify the cause of patients' infections.

The White House has asked for $2.5 billion in funding to address the COVID-19 outbreak, according to the Associated Press.

A resignation at the Marine Biological Laboratory highlights that institutions are unsure of how to handle researchers previously found to have violated codes of conduct, Nature News says.

In PNAS this week: immune responses that affect heart transplant rejection risk, gene variants associated with thiopurine toxicity, and more.